Sam Brusco, Associate Editor11.18.22
Millstone Medical Outsourcing has completed its acquisition of MycoScience.
MycoScience specializes in medical device and pharma lab testing, environmental testing, and regulatory support services. The company is an ISO 13485:2016 certified contract manufacturing organization.
The addition adds advanced lab and environmental testing services as well as long-standing industry and regulatory experience. It also boosts Millstone’s prowess in comprehensive end-to-end service through its Tier 1 approach to sourcing and support.
"With the acquisition of MycoScience, we can offer our customers more support and better controls around product testing, with a single expert point of contact," Millstone Medical Outsourcing CEO Karl Neuberger told the press. "The more advanced and thorough post-manufacturing and aftermarket services we can offer our customers, the more we can support them in creating and accelerating products that change patients' lives. This acquisition brings together two companies aligned on commitment to quality, expertise, and outstanding customer service."
MycoScience's leadership team will remain at the helm. MycoScience CEO Sarath Koruprolu noted, "Over the last 30 years, MycoScience has helped our customers bring amazing new devices and medicines to market for better patient outcomes. Now, as we begin a new chapter with Millstone, we look forward to continuing to apply our expertise to product testing, quality, and advancements as a part of the industry partner of choice."
MycoScience specializes in medical device and pharma lab testing, environmental testing, and regulatory support services. The company is an ISO 13485:2016 certified contract manufacturing organization.
The addition adds advanced lab and environmental testing services as well as long-standing industry and regulatory experience. It also boosts Millstone’s prowess in comprehensive end-to-end service through its Tier 1 approach to sourcing and support.
"With the acquisition of MycoScience, we can offer our customers more support and better controls around product testing, with a single expert point of contact," Millstone Medical Outsourcing CEO Karl Neuberger told the press. "The more advanced and thorough post-manufacturing and aftermarket services we can offer our customers, the more we can support them in creating and accelerating products that change patients' lives. This acquisition brings together two companies aligned on commitment to quality, expertise, and outstanding customer service."
MycoScience's leadership team will remain at the helm. MycoScience CEO Sarath Koruprolu noted, "Over the last 30 years, MycoScience has helped our customers bring amazing new devices and medicines to market for better patient outcomes. Now, as we begin a new chapter with Millstone, we look forward to continuing to apply our expertise to product testing, quality, and advancements as a part of the industry partner of choice."
